{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T19:53:37Z","timestamp":1794081217781,"version":"4.8.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This trial compared antithymocyte globulin (ATG) + cyclosporine A (CsA) + avatrombopag (AVA) and CsA + AVA in older adults with severe aplastic anemia (SAA). The patients were randomized to receive either ATG + CsA + AVA or CsA + AVA. Of 84 included patients, 42 were treated with ATG + CsA + AVA and 42 with CsA + AVA. With a median follow-up of 13 (0.3\u201317) months, the objective response rates (ORRs) at 3, 6, and 12\u2009months and the end of follow-up were 53.7%, 65.9%, 80.6%, and 71.4% in the ATG + CsA + AVA group and 61.9%, 73.2%, 77.4%, and 64.3% in the CsA + AVA group, respectively (P\u2009&gt;\u20090.05 at any time point). Three-month ORR was an independent predictor of 6-month complete response rates (P\u2009=\u20090.019). Patients in the ATG + CsA + AVA group showed a higher incidence of adverse events than those in the CsA + AVA group (64.3% vs. 35.7%, P\u2009=\u20090.009). The rates of relapse (P\u2009=\u20090.667), mortality (P\u2009=\u20091.000) and clonal evolution (P\u2009=\u20091.000) were comparable between the groups. The combination of CsA + AVA achieved comparable efficacy with superior safety compared to the combination of ATG + CsA + AVA in older adults newly diagnosed with SAA.<\/jats:p>","DOI":"10.1038\/s41408-025-01328-3","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T06:05:44Z","timestamp":1751695544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of immunosuppressive therapy versus cyclosporine combined with avatrombopag in older adults with severe aplastic anemia: a multicenter prospective study"],"prefix":"10.1038","volume":"15","author":[{"given":"Leyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengkui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,5]]},"reference":[{"key":"1328_CR1","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMra1413485","volume":"379","author":"NS Young","year":"2018","unstructured":"Young NS. Aplastic anemia. N Engl J Med. 2018;379:1643\u201356.","journal-title":"N Engl J Med"},{"key":"1328_CR2","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1182\/blood-2011-12-274019","volume":"120","author":"P Scheinberg","year":"2012","unstructured":"Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012;120:1185\u201396.","journal-title":"Blood"},{"key":"1328_CR3","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1056\/NEJMoa1103975","volume":"365","author":"P Scheinberg","year":"2011","unstructured":"Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011;365:430\u20138.","journal-title":"N Engl J Med"},{"key":"1328_CR4","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/bjh.13297","volume":"169","author":"C Dufour","year":"2015","unstructured":"Dufour C, Pillon M, Soci\u00e8 G, Rov\u00f2 A, Carraro E, Bacigalupo A, et al. Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant. Br J Haematol. 2015;169:565\u201373.","journal-title":"Br J Haematol"},{"key":"1328_CR5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/ejh.12590","volume":"96","author":"M Chen","year":"2016","unstructured":"Chen M, Liu C, Zhuang J, Zou N, Xu Y, Zhang W, et al. Long-term follow-up study of porcine anti-human thymocyte immunoglobulin therapy combined with cyclosporine for severe aplastic anemia. Eur J Haematol. 2016;96:291\u20136.","journal-title":"Eur J Haematol"},{"key":"1328_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.leukres.2018.01.001","volume":"65","author":"M Chen","year":"2018","unstructured":"Chen M, Liu C, Qiao X, Zhou D, Zhuang J, Han B. Comparative study of porcine anti-human lymphocyte immunoglobulin and rabbit anti-human thymocyte immunoglobulin as a first-line treatment of acquired severe aplastic anemia. Leuk Res. 2018;65:55\u201360.","journal-title":"Leuk Res"},{"key":"1328_CR7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/bjh.12772","volume":"165","author":"IS Hitchcock","year":"2014","unstructured":"Hitchcock IS, Kaushansky K. Thrombopoietin from beginning to end. Br J Haematol. 2014;165:259\u201368.","journal-title":"Br J Haematol"},{"key":"1328_CR8","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","volume":"104","author":"W Ghanima","year":"2019","unstructured":"Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB. Thrombopoietin receptor agonists: ten years later. Haematologica. 2019;104:1112\u201323.","journal-title":"Haematologica"},{"key":"1328_CR9","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40265-021-01553-7","volume":"81","author":"J Gilreath","year":"2021","unstructured":"Gilreath J, Lo M, Bubalo J. Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists. Drugs. 2021;81:1285\u2013305.","journal-title":"Drugs"},{"key":"1328_CR10","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.2147\/DDDT.S299591","volume":"15","author":"JB Bussel","year":"2021","unstructured":"Bussel JB, Soff G, Balduzzi A, Cooper N, Lawrence T, Semple JW. A review of romiplostim mechanism of action and clinical applicability. Drug Des Devel Ther. 2021;15:2243\u201368.","journal-title":"Drug Des Devel Ther"},{"key":"1328_CR11","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s40265-021-01575-1","volume":"81","author":"YY Syed","year":"2021","unstructured":"Syed YY. Hetrombopag: first approval. Drugs. 2021;81:1581\u20135.","journal-title":"Drugs"},{"key":"1328_CR12","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","volume":"376","author":"DM Townsley","year":"2017","unstructured":"Townsley DM, Scheinberg P, Winkler T, Desmond R, Dumitriu B, Rios O, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376:1540\u201350.","journal-title":"N Engl J Med"},{"key":"1328_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2109965","volume":"386","author":"R Peffault de Latour","year":"2022","unstructured":"Peffault de Latour R, Kulasekararaj A, Iacobelli S, Terwel SR, Cook R, Griffin M, et al. Eltrombopag added to immunosuppression in severe aplastic anemia. N Engl J Med. 2022;386:11\u201323.","journal-title":"N Engl J Med"},{"key":"1328_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/ejh.14021","volume":"111","author":"M Chen","year":"2023","unstructured":"Chen M, Liu Q, Gao Y, Suo X, Ding X, Wang L, et al. Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: a multicenter real-world retrospective study. Eur J Haematol. 2023;111:407\u201313.","journal-title":"Eur J Haematol"},{"key":"1328_CR15","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s40265-015-0363-4","volume":"75","author":"PL McCormack","year":"2015","unstructured":"McCormack PL. Eltrombopag: a review of its use in patients with severe aplastic anaemia. Drugs. 2015;75:525\u201331.","journal-title":"Drugs"},{"key":"1328_CR16","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s40265-018-0949-8","volume":"78","author":"M Shirley","year":"2018","unstructured":"Shirley M. Avatrombopag: first global approval. Drugs. 2018;78:1163\u20138.","journal-title":"Drugs"},{"key":"1328_CR17","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s40265-021-01613-y","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham A. Avatrombopag: a review in thrombocytopenia. Drugs. 2021;81:1905\u201313.","journal-title":"Drugs"},{"key":"1328_CR18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/bjh.15573","volume":"183","author":"W Jurczak","year":"2018","unstructured":"Jurczak W, Chojnowski K, Mayer J, Krawczyk K, Jamieson BD, Tian W, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018;183:479\u201390.","journal-title":"Br J Haematol"},{"key":"1328_CR19","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1182\/blood-2013-07-514398","volume":"123","author":"JB Bussel","year":"2014","unstructured":"Bussel JB, Kuter DJ, Aledort LM, Kessler CM, Cuker A, Pendergrass KB, et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014;123:3887\u201394.","journal-title":"Blood"},{"key":"1328_CR20","doi-asserted-by":"publisher","first-page":"204062072311913","DOI":"10.1177\/20406207231191310","volume":"14","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Hu Q, Yang C, Chen M, Han B. Comparison of eltrombopag and avatrombopag in the treatment of refractory\/relapsed aplastic anemia: a single-center retrospective study in China. Ther Adv Hematol. 2023;14:20406207231191310.","journal-title":"Ther Adv Hematol"},{"key":"1328_CR21","unstructured":"Song AB, Al-Samkari H. Chemotherapy-induced thrombocytopenia: modern diagnosis and treatment. Br J Haematol."},{"key":"1328_CR22","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1016\/S2352-3026(22)00001-1","volume":"9","author":"H Al-Samkari","year":"2022","unstructured":"Al-Samkari H, Kolb-Sielecki J, Safina SZ, Xue X, Jamieson BD. Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2022;9:e179\u2013e189.","journal-title":"Lancet Haematol"},{"key":"1328_CR23","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1007\/s12325-021-01752-4","volume":"38","author":"P Wojciechowski","year":"2021","unstructured":"Wojciechowski P, Wilson K, Nazir J, Pustu\u0142ka I, Tytu\u0142a A, Smela B, et al. Efficacy and safety of avatrombopag in patients with chronic immune thrombocytopenia: a systematic literature review and network meta-analysis. Adv Ther. 2021;38:3113\u201328.","journal-title":"Adv Ther"},{"key":"1328_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/14656566.2020.1841748","volume":"22","author":"ZM Virk","year":"2021","unstructured":"Virk ZM, Kuter DJ, Al-Samkari H. An evaluation of avatrombopag for the treatment of thrombocytopenia. Expert Opin Pharmacother. 2021;22:273\u201380.","journal-title":"Expert Opin Pharmacother"},{"key":"1328_CR25","doi-asserted-by":"crossref","unstructured":"Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A.et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172:187\u2013207.","DOI":"10.1111\/bjh.13853"},{"key":"1328_CR26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr. 2021;112:90\u201392.","journal-title":"Actas Dermosifiliogr"},{"key":"1328_CR27","doi-asserted-by":"publisher","first-page":"2424451","DOI":"10.1080\/07853890.2024.2424451","volume":"56","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Hu Q, Wang L, Yang C, Chen M, Han B. Cyclosporine plus avatrombopag versus cyclosporine monotherapy for first-line treatment of elderly patients with transfusion-dependent non-severe aplastic anemia: a single center retrospective study. Ann Med. 2024;56:2424451.","journal-title":"Ann Med"},{"key":"1328_CR28","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.exphem.2022.11.002","volume":"117","author":"Y Chi","year":"2023","unstructured":"Chi Y, Hu Q, Yang C, Chen M, Han B. Avatrombopag is effective in patients with chemoradiotherapy-induced aplastic anemia: a single-center, retrospective study. Exp Hematol. 2023;117:62\u201368.","journal-title":"Exp Hematol"},{"key":"1328_CR29","doi-asserted-by":"publisher","first-page":"90","DOI":"10.2478\/jtim-2023-0006","volume":"11","author":"H Wang","year":"2023","unstructured":"Wang H, He G, Jia J, Liu M, Liu H, Wang T, et al. Efficacy and safety of avatrombopag in aplastic anemia patients with liver disease. J Transl Int Med. Mar. 2023;11:90\u201393.","journal-title":"J Transl Int Med. Mar"},{"key":"1328_CR30","doi-asserted-by":"publisher","first-page":"104670","DOI":"10.1016\/j.exphem.2024.104670","volume":"140","author":"J Li","year":"2024","unstructured":"Li J, Liang W, Fan H, Zhou K, Li Y, Yang W, et al. Efficacy and safety of avatrombopag in combination with standard immunosuppressive therapy for severe aplastic anemia. Exp Hematol. 2024;140:104670.","journal-title":"Exp Hematol"},{"key":"1328_CR31","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/S2352-3026(23)00395-2","volume":"11","author":"P Scheinberg","year":"2024","unstructured":"Scheinberg P, Finelli C, Monta\u0148o-Figueroa EH, Vallejo C, Norasetthada L, Calado RT, et al. Activity and safety of eltrombopag in combination with cyclosporin A as first\u2011line treatment of adults with severe aplastic anaemia (SOAR): a phase 2, single-arm study. Lancet Haematol. 2024;11:e206\u2013e215.","journal-title":"Lancet Haematol"},{"key":"1328_CR32","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s00277-022-04780-4","volume":"101","author":"YY Hwang","year":"2022","unstructured":"Hwang YY, Chan TSY, Chan FHY, Lau CWP, Luk YY, Lau GWN, et al. Eltrombopag as frontline treatment of aplastic anaemia in routine practice: implications on cost and efficacy. Ann Hematol. 2022;101:1163\u201372.","journal-title":"Ann Hematol"},{"key":"1328_CR33","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/ajh.27611","volume":"100","author":"B Fattizzo","year":"2025","unstructured":"Fattizzo B, Gurnari C, Giammarco S, Ricchiuti A, Awada H, Bortolotti M, et al. Elderly patients with aplastic anemia: treatment patterns and outcomes in the real world. Am J Hematol. 2025;100:584\u201391.","journal-title":"Am J Hematol"},{"key":"1328_CR34","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/bjh.19648","volume":"205","author":"A Prabahran","year":"2024","unstructured":"Prabahran A, Durrani J, Coelho-Da Silva J, Shalhoub R, Lotter J, Rios O, et al. Safety and efficacy of immunosuppressive therapy for elderly patients with severe aplastic anaemia. Br J Haematol. 2024;205:1170\u20139.","journal-title":"Br J Haematol"},{"key":"1328_CR35","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1001\/jama.289.9.1130","volume":"289","author":"S Rosenfeld","year":"2003","unstructured":"Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003;289:1130\u20135.","journal-title":"JAMA"},{"key":"1328_CR36","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0037-1963(00)90033-7","volume":"37","author":"G Soci\u00e9","year":"2000","unstructured":"Soci\u00e9 G, Rosenfeld S, Frickhofen N, Gluckman E, Tichelli A. Late clonal diseases of treated aplastic anemia. Semin Hematol. 2000;37:91\u2013101.","journal-title":"Semin Hematol"},{"key":"1328_CR37","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1200\/JCO.22.00710","volume":"41","author":"C Gurnari","year":"2023","unstructured":"Gurnari C, Pagliuca S, Prata PH, Galimard JE, Catto LFB, Larcher L, et al. Clinical and molecular determinants of clonal evolution in aplastic anemia and paroxysmal nocturnal hemoglobinuria. J Clin Oncol. 2023;41:132\u201342.","journal-title":"J Clin Oncol"},{"key":"1328_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.884312","volume":"13","author":"R Li","year":"2022","unstructured":"Li R, Zhou J, Liu Z, Chen X, Long Q, Yang Y, et al. Predicting response of severe aplastic anemia to rabbit-antithymocyte immunoglobulin based immunosuppressive therapy combined with eltrombopag. Front Immunol. 2022;13:884312.","journal-title":"Front Immunol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01328-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01328-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01328-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T06:05:45Z","timestamp":1751695545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01328-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,5]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1328"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01328-3","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,5]]},"assertion":[{"value":"1 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"119"}}